A case of multiple myeloma with navicular bone involvement

Esra Yildizhan; Leylagul Kaynar; Nicolette Tiren; Ozlem Canoz; Bulent Eser

doi:10.1177/0036933017727962

A case of multiple myeloma with navicular bone involvement

Scott Med J. 2017 Nov;62(4):152-155. doi: 10.1177/0036933017727962. Epub 2017 Sep 29.

Authors

Esra Yildizhan¹, Leylagul Kaynar², Nicolette Tiren¹, Ozlem Canoz³, Bulent Eser⁴

Affiliations

¹ 1 MD, Hematologist, Erciyes University School of Medicine, Hematology Department, M. Kemal Dedeman Oncology Hospital, Kayseri, Turkey.
² 2 2 MD, Assoc. prof, Erciyes University School of Medicine, Hematology Department, M. Kemal Dedeman Oncology Hospital, Kayseri, Turkey.
³ 3 MD, Prof., Erciyes University School of Medicine, Pathology Department, Gevher Nesibe Hospital Kayseri, Turkey.
⁴ 4 MD, Prof., Erciyes University School of Medicine, Hematology Department, M. Kemal Dedeman Oncology Hospital, Kayseri, Turkey.

PMID: 28959919
DOI: 10.1177/0036933017727962

Abstract

Multiple myeloma is a haematological disease caused by proliferation of malignant plasma cells in bone marrow. It frequently has lytic bone lesions. However, involvement of the small bones of the hands and feet is extremely rare. We report a unique multiple myeloma patient with first recurrence in navicular bone after allogenic stem cell transplantation.

Keywords: Multiple myeloma; navicular bone.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols
Bone Neoplasms / complications
Bone Neoplasms / pathology*
Bone Neoplasms / therapy
Humans
Immunologic Factors / therapeutic use
Lenalidomide
Male
Multiple Myeloma / complications
Multiple Myeloma / pathology*
Multiple Myeloma / therapy
Osteolysis / pathology
Plasma Cells / pathology*
Remission Induction
Stem Cell Transplantation / adverse effects*
Tarsal Bones / pathology*
Thalidomide / analogs & derivatives
Thalidomide / therapeutic use

Substances

Immunologic Factors
Thalidomide
Lenalidomide